Vaxcyte, Inc. - Common Stock, $0.001 par value per share (PCVX)
CUSIP: 92243G108
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Shares outstanding
- 145,782,011
- Total 13F shares
- 147,544,352
- Share change
- +4,973,518
- Total reported value
- $6,807,567,166
- Put/Call ratio
- 166%
- Price per share
- $46.14
- Number of holders
- 292
- Value change
- +$262,484,457
- Number of buys
- 139
- Number of sells
- 150
Quarterly Holders Quick Answers
What is CUSIP 92243G108?
CUSIP 92243G108 identifies PCVX - Vaxcyte, Inc. - Common Stock, $0.001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 92243G108:
Top shareholders of PCVX - Vaxcyte, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. |
13D/G
13F
|
Company |
8.6%
|
11,296,333
|
$520,196,135 | +$137,268,465 | 31 Dec 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
9%
|
13,104,203
|
$472,046,873 | — | 30 Sep 2025 | |
| FMR LLC |
13F
|
Company |
8.6%
|
12,509,933
|
$450,607,771 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
8.5%
|
12,320,453
|
$443,782,718 | — | 30 Sep 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
8.2%
|
11,965,991
|
$431,014,996 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
7.6%
from 13D/G
|
9,955,978
|
$358,614,332 | — | 30 Sep 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
3.5%
|
5,032,771
|
$181,280,411 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
3.3%
|
4,785,889
|
$172,387,722 | — | 30 Sep 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
2.9%
|
4,290,790
|
$154,554,256 | — | 30 Sep 2025 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
2.6%
|
3,784,755
|
$136,326,875 | — | 30 Sep 2025 | |
| WESTFIELD CAPITAL MANAGEMENT CO LP |
13F
|
Company |
2.6%
|
3,732,715
|
$134,452,394 | — | 30 Sep 2025 | |
| Kynam Capital Management, LP |
13F
|
Company |
2.1%
|
3,071,588
|
$110,638,600 | — | 30 Sep 2025 | |
| Deep Track Capital, LP |
13F
|
Company |
2.1%
|
3,000,000
|
$108,060,000 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2%
|
2,884,040
|
$103,898,128 | — | 30 Sep 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.2%
|
1,688,483
|
$60,820,000 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.1%
|
1,565,036
|
$56,372,597 | — | 30 Sep 2025 | |
| Eversept Partners, LP |
13F
|
Company |
0.98%
|
1,421,983
|
$51,219,828 | — | 30 Sep 2025 | |
| Pivotal bioVenture Partners Investment Advisor LLC |
13F
|
Company |
0.94%
|
1,372,425
|
$49,434,749 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.89%
|
1,293,407
|
$46,588,520 | — | 30 Sep 2025 | |
| MAVERICK CAPITAL LTD |
13F
|
Company |
0.88%
|
1,289,567
|
$46,450,203 | — | 30 Sep 2025 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
0.8%
|
1,170,899
|
$42,175,782 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.74%
|
1,073,346
|
$38,661,924 | — | 30 Sep 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.71%
|
1,029,629
|
$37,087,237 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.67%
|
975,377
|
$35,133,079 | — | 30 Sep 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.65%
|
949,049
|
$34,184,000 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.65%
|
948,967
|
$34,181,791 | — | 30 Sep 2025 | |
| Novo Holdings A/S |
13F
|
Company |
0.63%
|
916,160
|
$33,000,083 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.58%
|
847,573
|
$30,529,579 | — | 30 Sep 2025 | |
| Capital Research Global Investors |
13F
|
Company |
0.58%
|
842,978
|
$30,364,068 | — | 30 Sep 2025 | |
| Saturn V Capital Management LP |
13F
|
Company |
0.54%
|
788,441
|
$28,399,645 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.54%
|
784,483
|
$28,257,104 | — | 30 Sep 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.5%
|
722,793
|
$26,035,004 | — | 30 Sep 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.48%
|
696,843
|
$25,100,272 | — | 30 Sep 2025 | |
| BROWN ADVISORY INC |
13F
|
Company |
0.46%
|
676,985
|
$24,385,001 | — | 30 Sep 2025 | |
| COMERICA BANK |
13F
|
Company |
0.45%
|
654,369
|
$23,570,382 | — | 30 Sep 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.44%
|
640,885
|
$23,084,678 | — | 30 Sep 2025 | |
| Jeff Fairman |
3/4/5
|
VP, Research |
—
mixed-class rows
|
369,054
mixed-class rows
|
$22,935,618 | — | 30 Dec 2022 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.44%
|
635,070
|
$22,875,222 | — | 30 Sep 2025 | |
| Logos Global Management LP |
13F
|
Company |
0.43%
|
625,000
|
$22,512,500 | — | 30 Sep 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.38%
|
553,849
|
$19,949,641 | — | 30 Sep 2025 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
0.36%
|
528,853
|
$19,049,285 | — | 30 Sep 2025 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.36%
|
519,734
|
$18,720,819 | — | 30 Sep 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.33%
|
484,638
|
$17,456,661 | — | 30 Sep 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
0.33%
|
474,405
|
$17,088,068 | — | 30 Sep 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.3%
|
439,612
|
$15,834,836 | — | 30 Sep 2025 | |
| Polar Capital Holdings Plc |
13F
|
Company |
0.29%
|
415,530
|
$14,967,391 | — | 30 Sep 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.27%
|
398,480
|
$14,353,250 | — | 30 Sep 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.27%
|
398,144
|
$14,341,147 | — | 30 Sep 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.27%
|
397,789
|
$14,328,360 | — | 30 Sep 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.27%
|
393,914
|
$14,188,784 | — | 30 Sep 2025 |
Institutional Holders of Vaxcyte, Inc. - Common Stock, $0.001 par value per share (PCVX) as of Q4 2025
As of 31 Dec 2025,
Vaxcyte, Inc. - Common Stock, $0.001 par value per share (PCVX) was held by
292 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
147,544,352 shares.
The largest 10 holders included
FMR LLC, JANUS HENDERSON GROUP PLC, VANGUARD GROUP INC, T. Rowe Price Investment Management, Inc., RA CAPITAL MANAGEMENT, L.P., BlackRock, Inc., WELLINGTON MANAGEMENT GROUP LLP, STATE STREET CORP, Paradigm Biocapital Advisors LP, and Deep Track Capital, LP.
This page lists
292
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
282
Q4 2025 holders
292
Holder diff
10
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.